SP021 Bone marrow minimal residual disease (MRD) was the strongest predictor of survival from high risk metastatic neuroblastoma (NB) following anti-GD2 immunotherapy, when tested in multivariate models that include FcR polymorphism and missing ligand for inhibitory killer-immunoglobulin-like receptor (KIR)

✍ Scribed by Cheung, N.; Cheung, I.; Kuk, D.; Ostrovnaya, I.; Modak, S.; Kramer, K.; Kushner, B.

• Book ID: 122230727
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 51 KB
• Volume: 49
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/S0959-8049(13)70099-6